Results 191 to 200 of about 4,620,636 (276)

Exploring new avenues: Psychedelic‐assisted therapy for young people

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou   +3 more
wiley   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

Plasma and breast milk pharmacokinetics of suvorexant in healthy lactating women

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This paper aims to evaluate the plasma and breast milk pharmacokinetics of suvorexant, an orexin receptor antagonist used to treat insomnia at a maximum dose of 20 mg, in healthy lactating women. Methods The paper reports on an open‐label Phase 1 study in 12 healthy lactating women.
Jacqueline McCrea   +10 more
wiley   +1 more source

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy